CC
NMRA icon

Corton Capital’s Neumora Therapeutics NMRA Stock Holding History

Corton Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-51,561
Closed -$681K – 557
2024
Q3 		$681K Buy
51,561
+20,377
+65% +$238K 0.33% 19
2024
Q2 		$307K Buy
+31,184
New +$323K 0.16% 181

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Corton Capital's NMRA Position: Q4 2024 in Review

Corton Capital sold out of Neumora Therapeutics (NMRA) in Q4 2024, closing a stake of 51,561 shares — an estimated $681K sold.

Corton Capital first reported a position in NMRA in Q2 2024 and held it in 2 quarters. The position peaked at $681K in Q3 2024. 134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

  • Corton Capital reported no remaining Neumora Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Corton Capital sold 51,561 Neumora Therapeutics shares in Q4 2024, an estimated $681K.
  • Corton Capital first reported a position in Neumora Therapeutics in Q2 2024 and held it in 2 quarters.
  • Corton Capital's Neumora Therapeutics position peaked at $681K in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.